On-Demand WebinarNovel treatments are emerging to tackle cardiovascular and metabolic diseases, including Metabolic Associated Steatohepatitis (MASH), a fatty liver disease. However, existing in vitro models often fall short in accurately predicting human responses when testing such new treatments. To holistically assess the full potential of new therapies, it's critical to assess both efficacy and toxicity in hepatic and extra-hepatic tissues. For this, a comprehensive approach that models the disease progression in a physiologically relevant 3D environment is key.Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.Webinar Highlights- Comprehensive in vitro modeling of MASH, including liver steatosis and vascular inflammation.- MIMETAS’s expertise in disease modeling capabilities for metabolic and cardiovascular diseases.- Insights into the efficacy and toxicity of novel emerging therapies on both hepatic and extra-hepatic tissue.